Silexion Therapeutics Corp (NASDAQ:SLXN) Financings

Silexion Therapeutics Corp

Financings

RaiseDate
Ordinary shares on exercise of series E warrants
Announced: US$837,366 · US$0.2603 a share · Warrants at US$0.2603 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital for general corporate purposes
Sep 29, 2026
Public offering of ordinary shares
Closed: US$2.5M raised · US$0.65 a share · Warrants at US$0.65 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Strengthen the balance sheet, support the Phase 2/3 trial of SIL204 and support Nasdaq continued listing compliance
Aug 14, 2026
Public offering of ordinary shares (or ordinary share equivalents) with series A and series B warrants
Announced: US$6M · US$4 a share · Warrants at US$4 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Advance pre-clinical studies and general corporate purposes
Sep 11, 2025
Warrant exercise of ordinary shares on exercise of warrants
Announced: about US$1.8M · US$11.57 a share · Warrants at US$11.32 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital for general corporate purposes
Aug 1, 2025
Warrant exercise of ordinary shares on exercise of outstanding warrants
Announced: about US$3.3M · US$1.35 a share · Warrants at US$1.5 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital for general corporate purposes
Jan 29, 2025
Public offering of ordinary shares (or ordinary share equivalents) and warrants
Announced: about US$5M · US$1.35 a share · Warrants at US$1.35 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Advance pre-clinical studies and general corporate purposes
Jan 15, 2025

Read by 6ix AI from the company's releases